Tarlatamab (AMG757), a DLL3-targeting BiTE engineered by Giffin’s team, demonstrates enhanced pharmacokinetics and low picomolar potency against SCLC cells in vitro, coupled with robust tumor growth inhibition in preclinical models (75). Here, DLL3 is linked to neoplasm.